Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Predictive Oncology Inc.’s Subsidiaries Soluble Biotech Inc. and TumorGenesis Inc. are both constructing new GMP labs

Published

on

MINNEAPOLIS, June 22, 2021 (GLOBE NEWSWIRE) — Predictive Oncology (NASDAQ: POAI), an AI-driven oncology and drug discovery company, announced today that two of their wholly owned subsidiaries, Soluble Biotech Inc. and TumorGenesis Inc. are both expanding their unique services by completing the fabrication and qualification of GMP facilities.

Soluble Biotech Inc., located in Birmingham, Alabama, uses a proprietary technology to rapidly develop formulations for protein and peptide therapeutics (i.e., vaccines, antibodies, virus-like particles, etc.). The GMP facility will allow the company to provide their customers with formulations that can be directly used in clinical trials. This new capability is expected to significantly expand Soluble Biotech’s growing potential customer base and it is hoped to lead to long-term partnerships with pharmaceutical and biotech companies. Soluble Biotech also sells chromatography kits that contain their proprietary, highly efficient endotoxin removal media. Soluble’s new GMP facility will be used to produce this media for pharmaceutical and biotechnology companies as one of their final protein purification steps prior to entering animal or human trials.

“The addition of a GMP facility is expected to significantly increase our potential customer base and lead to multiple long-term collaborations,” said Dr. Larry DeLucas, Vice President of Operations at Predictive Oncology.

TumorGenesis Inc., located in Salem, Massachusetts, is also implementing GMP operations for its production of cancer cell media and other products used in the capture, culture, identification, and screening of ovarian and breast cancer cells. The media, used to “fool” cancer cells into behaving as if they were still in the body, can also be used along with new technologies in cancer cell editing to produce proteins and other biological products that can be used to diagnose, treat, or modify cancer cells.

“By having the ability to scale into GMP production of media, we will be able to meet the needs of researchers who are exploring ways to use the cancer cell’s own mechanisms to produce a target, expressed protein or biological target,” said Richard Gabriel, Senior Vice President of Research and Development at Predictive Oncology.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward- looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements because of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Landon Capital
Keith Pinder
(404) 995-6671
[email protected]

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Kharon Data and Technology Selected by U.S. Department of the Treasury

Published

on

kharon-data-and-technology-selected-by-us.-department-of-the-treasury

Treasury officers will gain access to Kharon’s platform for sanctions-related risk intelligence
WASHINGTON, May 7, 2024 /PRNewswire/ — Kharon announces the signing of a contract with the U.S. Department of the Treasury. Through this engagement, officials within the Treasury Department will gain access to Kharon’s global risk analytics platform. Kharon’s insights and analytic tools are used by leading financial institutions, companies, and governments to address global security threats, and to support risk management in connection with KYC, transaction screening, sanctions evasion, investigations, and trade controls.

This award underscores Kharon’s commitment to helping organizations navigate the complexities of sanctions compliance and combatting sanctions evasion, including the OFAC and EU 50 percent rules, FinCEN alerts on Harmonized System (HS) codes and export control evasion, and countering terrorist financing.
Alongside a recent award with the U.S. Customs and Border Protection, this engagement with the Treasury Department expands the U.S. Government’s access to Kharon insights, data analytics, and investigative workflow tools for critical public sector security objectives.
Kharon’s expertise in generating data-driven insights will assist the Treasury Department with its mission of disrupting the financial operations that underpin the networks of foreign actors tied to global security threats, including terrorism, nuclear and missile proliferation, Russia’s invasion of Ukraine, human rights violators, transnational crime, corruption, and others. Kharon insights draw upon all available open-source information and are powered by world-class subject matter expertise and data analytics combined with cutting-edge AI and natural language processing (NLP) systems. Kharon has been awarded multiple patents for its transformative analytic and workflow tools that have helped leading banks and corporates minimize risk and maximize efficiency for critical compliance, investigative, and risk management functions.
“Effectively implementing sanctions and trade controls requires both public and private sector organizations to have the insights needed to counter evasion,” said Howard Mendelsohn, Kharon’s Chief Client Officer. “This award represents an additional step in aligning critical insights across the public and private sectors. We are proud to support the U.S. Department of the Treasury in its critical mission.”
About Kharon
Kharon helps leading organizations identify a wide range of sanctions and compliance risks, critical to managing financial crimes, supply chain exposure, export controls, investment risk, and more. Combining cutting-edge technology and data science with industry-leading research, our solutions provide the critical insights required for a comprehensive view of illicit finance and other commercial threats.
The Kharon leadership team includes former senior officials from the U.S. Government who have leveraged their unique expertise to build risk management solutions that are trusted by the world’s top financial institutions, global corporates, and professional services firms.
Visit Kharon.com and follow Kharon on LinkedIn to learn more.
Media Contacts [email protected]
Logo – https://mma.prnewswire.com/media/1283302/Kharon_logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/kharon-data-and-technology-selected-by-us-department-of-the-treasury-302137445.html

Continue Reading

Artificial Intelligence

Imaging Endpoints Unveils New Initiative with Revolution Endpoints™, an Investment Subsidiary to Accelerate Innovation and Growth

Published

on

imaging-endpoints-unveils-new-initiative-with-revolution-endpoints™,-an-investment-subsidiary-to-accelerate-innovation-and-growth

SCOTTSDALE, Ariz., May 7, 2024 /PRNewswire/ — Imaging Endpoints (IE), a global leader in Imaging CRO technologies and services, has announced the formation of a new subsidiary, Revolution Endpoints, focused on leveraging the Company’s strong leadership and financial position to acquire synergistic technologies and services. This initiative aims to further advance the company’s internal research programs targeted toward development of cutting-edge service offerings.

Revolution Endpoints is already meticulously evaluating emerging technologies for adoption while exploring licensing, partnership, or acquisition of the most promising and synergetic opportunities. By identifying and integrating emerging technologies that complement internal development efforts and existing services, Imaging Endpoints intends to ensure it continues to lead the industry in service offerings.
Doug Dean Burkett, CEO and President of Imaging Endpoints commented: “For fifteen years we have been relentlessly executing on a consistent, unwavering strategy to organically grow our leadership in oncology-focused imaging CRO services. We are now generally recognized as leading the industry in science and quality, and our efforts have yielded remarkable growth.  We are fortunate to be in a position to invest in emerging technologies that are synergistic with our own development projects and our vision to Connect Imaging to the Cure™. Through this new subsidiary, we are excited to explore new frontiers, support transformative ideas, and continue our mission of advancing healthcare and improving patient outcomes.”
IE believes in the power of collaboration and innovation to drive progress in the fight against cancer. Revolution Endpoints is engaging with emerging technology leaders within AI assisted image evaluation, quantitative biomarkers, big datasets, predictive analytics and NLP, 3D imaging, AR, VR, AI enhanced enterprise automation, and blockchain technology that have potential to further streamline and improve both image workflows and efficacy analysis. Service providers with synergistic technologies and service offerings may also be of interest.
For more information about Revolution Endpoints or to discuss your emerging technology with our experts, please visit Revolution Endpoints or contact us at [email protected]
About Imaging Endpoints
Imaging Endpoints (IE) is passionately focused on its vision to Connect Imaging to the Cure. With a flawless global inspection record and a 95% marketing authorization success rate, IE has a proven track record of supporting successful regulatory submissions across the globe. IE’s commitment to quality, innovation, and excellence has positioned it as the global leader in oncology imaging.
Imaging Endpoints is the largest oncology-focused Imaging CRO, with 8 offices strategically located across 6 countries including Scottsdale, AZ, Cambridge, MA; London, UK; Leiden, Netherlands; Basel, Switzerland; Hyderabad, India; and Shanghai, China.
IE is an affiliate of HonorHealth, one of the largest healthcare systems nationally, and also an affiliate of Southwest Medical Imaging, Ltd. (SMIL/RadPartners), part of the largest private radiology group in the U.S.
Media Contact
Contact No: 480.314.3070
Photo: https://mma.prnewswire.com/media/2405411/Imaging_Endpoints_Revolution.jpgLogo: https://mma.prnewswire.com/media/2405461/Imaging_Endpoints_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/imaging-endpoints-unveils-new-initiative-with-revolution-endpoints-an-investment-subsidiary-to-accelerate-innovation-and-growth-302138084.html

Continue Reading

Artificial Intelligence

ICIS Launches Ask ICIS Generative AI Commodities Assistant

Published

on

icis-launches-ask-icis-generative-ai-commodities-assistant

Global commodities intelligence provider launches generative AI assistant to boost access to expert insights and data around the global energy and chemicals markets
LONDON, May 7, 2024 /PRNewswire/ — ICIS, a global source of commodity intelligence, announced the launch of Ask ICIS, a first of its kind generative AI assistant that will enhance access to ICIS’ standout intelligence and insights for the energy and chemicals markets.

 
As commodity markets become more complex and dynamic, the need for both highly accurate and up-to-the-minute information has never been more important. Underpinned by unparalleled chemical and energy market datasets and decades of editorial expertise, Ask ICIS combines ICIS’ vast market intelligence with the power of generative AI technology.
Currently in beta, Ask ICIS is available in multiple languages and supported with citations, Ask ICIS allows customers to delve deeper, supporting timely, confident strategic decision-making with comprehensive market intelligence. 
“At ICIS, we are committed to delivering the best possible intelligence to our customers so that they can arrive at the best possible outcomes for the decisions they need to make,” said Jeff Skelton, CEO of ICIS. “Through Ask ICIS, we are taking our ambition one step further by unlocking access to our trusted and actionable insights to provide immediate and personalized responses to complex customer enquiries  in a fraction of the time. We are committed to helping our customers adopt and scale new technologies, enabling them to make better decisions and bring the maximum value possible to their organizations.”
Sourced exclusively from ICIS’ expert data and insight, Ask ICIS connects users to content tailored directly to their needs based on their role, region, and priorities. Source citations are built into every response allowing users to delve deeper and enabling more confident, timely, strategic decision-making. In addition, Ask ICIS also provides bespoke suggested prompts and follow-up questions to allow users to uncover additional insights and “unknown unknowns” to gain an unprecedented view and understanding of market events.
“To drive success in today’s commodity markets you need to have the most innovative tools and information at your disposal,” said Skelton. “We strongly believe that Ask ICIS not only helps our customers achieve new goals and levels of performance but has also sets a new bar for the way commodity markets can now access intelligence.”
For more information on ICIS please visit, www.icis.com. For more information on Ask ICIS, or if you are an ICIS customer  interested in joining the beta progam, please visit: https://www.icis.com/explore/contact/ask-icis/.
About ICIS
ICIS – Independent Commodity Intelligence Services – helps businesses through seamlessly delivering data and analytics, across the chemical, and energy markets. A trusted source and benchmark for price information and insight across key commodities markets worldwide. Our independent, transparent market intelligence informs thousands of quality decisions every day, taking the pressure out of negotiations and giving customers space for more innovative thinking, through published datasets including price assessments, price forecasts, supply and demand fundamentals and more.
Over 150 years of shaping the world by connecting markets to optimise the world’s valuable resources. With a global team of more than 600 experts, ICIS has employees based in London, New York, Houston, Karlsruhe, Milan, Mumbai, Singapore, Guangzhou, Beijing, Shanghai, Dubai, Sao Paulo, Seoul, Tokyo and Perth.
ICIS is part of RELX, a FTSE15 company with a market cap of $78.2bn and an employee base of over 30,000 experts across 40 countries.
About RELX
RELX is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs approximately 30,000 people of whom almost half are in North America. RELX PLC is a London listed holding company which owns 52.9% of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1% of RELX Group. The shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX and RENX. Total market capitalisation is approximately £62.4bn | €73bn | $78.2bn.
Logo: https://mma.prnewswire.com/media/619935/4277787/ICIS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/icis-launches-ask-icis-generative-ai-commodities-assistant-302135677.html

Continue Reading

Trending